Switch to:
More From Other Websites
Major Pharma Continues to See Rising Tide in Short Interest Sep 27 2016
Wall Street Sells Off on Worries Over Clinton-Trump Showdown Sep 26 2016
Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies Sep 26 2016
As Humira Alternative Gets FDA Approval, Is Abbvie in Trouble? Sep 26 2016
What’s the Upside Potential for Gilead? Sep 26 2016
AbbVie Showcases Commitment to Research and Innovation in Dermatology at the 25th European Academy... Sep 26 2016
AbbVie, Inc. breached its 50 day moving average in a Bearish Manner : ABBV-US : September 26, 2016 Sep 26 2016
AbbVie (ABBV) HCV Combination Drug Positive in Phase IIIb Sep 26 2016
Jefferies Makes Huge New Stock Addition to Franchise Picks List Sep 26 2016
7:05 am AbbVie submits a sNDA for ibrutinib to treat patients with marginal zone lymphoma Sep 26 2016
AbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA®) for... Sep 26 2016
Amgen's Biosimilar of Abbvie's Humira Gets FDA Approval Sep 26 2016
FDA Approves Amgen's Biosimilar Version of Humira Sep 23 2016
FDA approves lower-cost alternative to biotech drug Humira Sep 23 2016
FDA approves lower-cost alternative to biotech drug Humira Sep 23 2016
U.S. FDA approves Amgen's copy of AbbVie arthritis drug Humira Sep 23 2016
U.S. FDA approves Amgen's cheaper copy of arthritis drug Humira Sep 23 2016
Enanta Pharmaceuticals Announces Data on Eight-Week Treatment of AbbVie’s VIEKIRAX®... Sep 23 2016
AbbVie Presents Data on Eight-Week Treatment of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir... Sep 23 2016


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK